FIELD: medicine; oncology and gynaecology.
SUBSTANCE: 9-oxoacridine-10-acetic acid (A) and/or its pharmaceutically acceptable salt are introduced in combinations with antiestrogen and/or progestin in amount effective to potentiate action of the specified antiestrogen and/or progestin. Thus (A) and/or its salt and/or ester combined with antiestrogen and/or progestin can be used as a preparation or as sets. Application of A and/or its salts and/or esters provide inhibition of NF-kappaB protein.
EFFECT: intensified sensitivity of uterine body or breast cancer cells to antiproliferative action of antiestrogen and progestin.
17 cl, 1 dwg, 5 tbl, 12 ex
Authors
Dates
2009-02-20—Published
2007-03-29—Filed